You are looking after a 54 year old man post cadaveric liver transplantation with impaired graft function and failure to progress. A large subhepatic bile collection was drained percutaneously on day 7 when he was started on piperacillin-tazobactam. Culture of the drain fluid reveals heavy growth of Enterococcus spp.
- What activity does piperacillin have against Enterococcus spp?
- The Provisional report is that the Enterococcus is resistant to Vancomycin. List 3 antibiotics would you consider in this situation.
- What are the main toxicities of each of the antibiotics you have listed in your answer to b)?
- Which antibiotic would you select, and why?
Piperacillin activity is similar to penicillin, and less than that of ampicillin. Enterococci are relatively penicillin resistant; E. faecium is more resistant than E. faecalis. Most VRE have high-level resistance to β-lactams (and aminoglycosides).
The main options would be:
- ceftaroline (E.faecalis not faecium)
c) Main toxicities of each of the antibiotics:
- Teicoplanin: relatively little toxicity, less than vancomycin; thrombocytopenia, anaemia, renal or hepatic dysfunction
- Linezolid: mitochondrial toxin, hence thrombocytopenia, anaemia, peripheral or ocular neuropathy, lactic acidosis, serotonin syndrome
- Tigecycline: nausea & vomiting; teratogenic; catabolic, FDA reports increased risk of death in HAP or VAP compared to alternative treatments
- Daptomycin: myopathy
- Ceftaroline: no significant toxicity
A reasoned answer is required. Linezolid may be preferred over teicoplanin due to its greater efficacy and better tissue penetration (it is poorly protein bound, so volume of distribution approximates to total body water). No dosage reduction is necessary in renal or hepatic failure. Van A resistance is common in Australia, so many VRE are teicoplanin resistant. Tigecycline and daptomycin generally regarded as third line drugs. Ceftaroline new to practice and limited experience to date.
This bunch of cocci were previously known as Group D streptococci. They are not particularly pathogenic, but their intrinsic resistance to antibiotics makes them interesting to the intensivist.
a) Enterococci have intrinsic resistance to β-lactam antibiotics due to the low affinity of their penicillin-binding proteins for penicillin. Interestingly, piperacillin has approximately the same activity as benzylpenicillin against these enterococci; ticarcillin and cephalosporins have about four times less activity, and are thus essentially useless.
b) Antibiotic choices and their toxicities
As to this specific biliary sepsis patient? Their collection is VRE infected, and one needs a drug with good tissue penetration. The college have chosen linezolid.
Hollenbeck, Brian L., and Louis B. Rice. "Intrinsic and acquired resistance mechanisms in enterococcus." Virulence 3.5 (2012): 421-433.
Kaye, Donald. "Enterococci: biologic and epidemiologic characteristics and in vitro susceptibility." Archives of Internal Medicine 142.11 (1982): 2006-2009.
Wilson, A. P. R. "Comparative safety of teicoplanin and vancomycin."International journal of antimicrobial agents 10.2 (1998): 143-152.
Lawrence, Kenneth R., May Adra, and P. Ken Gillman. "Serotonin toxicity associated with the use of linezolid: a review of postmarketing data." Clinical infectious diseases 42.11 (2006): 1578-1583.
Attassi, Kinan, et al. "Thrombocytopenia associated with linezolid therapy."Clinical infectious diseases 34.5 (2002): 695-698.
Bressler, Adam M., et al. "Peripheral neuropathy associated with prolonged use of linezolid." The Lancet infectious diseases 4.8 (2004): 528-531.
Rucker, Janet C., et al. "Linezolid-associated toxic optic neuropathy."Neurology 66.4 (2006): 595-598.
Vinh, Donald C., and Ethan Rubinstein. "Linezolid: a review of safety and tolerability." Journal of Infection 59 (2009): S59-S74.
Arbeit, Robert D., et al. "The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections." Clinical Infectious Diseases38.12 (2004): 1673-1681.
Raja, Aarti, et al. "Daptomycin." Nature Reviews Drug Discovery 2.12 (2003): 943-944.
Stein, Gary E., and William A. Craig. "Tigecycline: a critical analysis." Clinical infectious diseases 43.4 (2006): 518-524.
Stein, Gary E., and Timothy Babinchak. "Tigecycline: an update." Diagnostic microbiology and infectious disease 75.4 (2013): 331-336.
Saravolatz, Louis D., Gary E. Stein, and Leonard B. Johnson. "Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus." Clinical infectious diseases 52.9 (2011): 1156-1163.